GlobeNewswire Inc.··Hagens BermanGossamer Bio Plummets 80% as Failed Phase 3 Trial Triggers Securities Lawsuit
Gossamer Bio faces class action lawsuit after Phase 3 PROSERA trial failure causes 80% stock collapse. Allegations include investor misleading on trial design and patient recruitment.
GOSSsecurities class actionstock price drop